Healthcare / BiotechnologyHKSE
$1.20
+0.01 (+0.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-172.3M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-20.7%
↓Gross Margin
N/A
•Debt/Equity
0.67
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-105.0M · FCF $-95.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $2.0M | $1.4M | — |
| Net Income | $-105.0M | $-105.0M | $-185.1M | $-243.1M | $-284.2M |
| EBITDA | $-72.1M | $-72.1M | $-146.2M | $-200.5M | $-251.2M |
| EPS | -0.09 | -0.09 | -0.17 | -0.24 | -0.29 |
| Gross Margin | — | — | 26.8% | 30.9% | — |
| Operating Margin | — | — | -7964.2% | -16818.7% | — |
| Net Margin | — | — | -9138.3% | -17810.3% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.67 | 0.67 | 2.50 | 1.53 | 0.70 |
| Current Ratio | 1.91 | 1.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-95.8M | $-95.8M | $-172.3M | $-237.7M | $-414.9M |
| Returns | |||||
| ROE | -20.7% | -20.7% | -96.0% | -82.2% | -55.8% |
| Valuation | |||||
| P/B | 2.90 | 2.90 | 5.62 | 5.68 | 3.85 |
| Growth & Yield | |||||
| Revenue Growth | — | — | 48.4% | — | — |
| EPS Growth | 47.1% | 47.1% | 29.2% | 17.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.17 → -0.09
Residual
-4.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.